Introduction

The U.S. Food and Drug Administration's (FDA) recent draft guidance on tissue biopsies in clinical trials represents a significant advancement in balancing ethical considerations with scientific integrity. This document focuses on the inclusion of biopsies for both adult and pediatric participants, highlighting risk mitigation, necessity, and purpose. While the guidance provides a strong foundation, it also reveals areas for enhancement that could redefine the future of clinical trial design.

Key Insights

The FDA draft underscores several core principles regarding the use of tissue biopsies:

• Prioritizing necessity, purpose, and risk assessment for biopsies in clinical trials for pediatric and adult populations.

• Requiring robust scientific justification and alternative approaches for high-risk biopsy sites.

• Encouraging early dialogue with regulatory divisions to refine trial design and justify the scientific requirement of biopsies.

• Mandating that pediatric biopsies provide direct benefits or minimal risk, with clear parental and patient consent.

• Emphasizing the importance of transparent informed consent that outlines risks and ensures optional biopsies do not influence trial participation.

The draft guidance offers insights on incorporating tissue biopsies into clinical trials. This guidance, once finalized, will offer direction to sponsors, clinical investigators, institutions, and Institutional Review Boards (IRBs) on key considerations when including biopsies in studies involving adults and children.

Role and Importance of Biopsies in Clinical Research

Tissue biopsies often play a critical role in clinical trials by helping to determine participant eligibility or assessing the impact of an investigational treatment. “Tissue biopsies in clinical trials are often needed to determine eligibility or to understand the effect of the medical product being studied in the trial,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research1.

The guidance calls for strong scientific justification for biopsies, particularly when alternative approaches exist or when the biopsies involve higher-risk tissue sites.

Recommendations for Biopsies in Adult Studies

For clinical trials involving adults, the guidance highlights the need to evaluate the purpose and necessity of biopsies, as well as their associated risks. If existing pathology specimens or less invasive methods cannot provide the required information, a biopsy may be warranted. In such cases, the scientific rationale for including the biopsy must be explicitly stated in the trial protocol.

The guidance also addresses the importance of clarity in statistical analysis plans, particularly when biopsy data are used for study endpoints. Biopsies intended for non-key secondary or exploratory endpoints should remain optional, and participants must be allowed to decline without jeopardizing their trial enrollment. Sponsors are encouraged to engage with the FDA early in the development process to discuss the need for biopsies and ensure alignment with regulatory requirements 2.

Ensuring Participant Safety and Consent

Protecting the rights and safety of trial participants is a primary responsibility of study investigators. Participants must be fully informed about the potential risks and benefits of biopsies through detailed informed consent documents. This documents should clearly explain any foreseeable physical or informational risks, ensuring that participants understand the procedure before agreeing to take part.

Specific Considerations for Pediatric Participants

Additional safeguards apply to studies involving children. When biopsies are performed solely for research and are not needed for clinical management, their inclusion must meet specific ethical and safety standards. If the biopsy provides a direct benefit to the child, the risks must be justified by the anticipated benefits, and the overall risk-benefit ratio must be comparable to or better than other available options.

If a biopsy does not offer direct benefits, its risks should either be minimal or represent only a slight increase over minimal risk. When this threshold cannot be met, the biopsy must contribute to critical knowledge about the disease that has the potential to significantly improve understanding or treatment. Factors such as the invasiveness of the procedure, the frequency of biopsies, and risks associated with sedation must be carefully considered when assessing risk for pediatric participants.

Parental and Patient Consent

The guidance emphasizes the role of IRBs in ensuring ethical practices in pediatric trials. Before performing a biopsy, both the parent or guardian’s permission and the child’s assent are required. Consent documents must outline any potential risks, discomforts, and benefits in clear terms to ensure all parties fully understand the implications.

Conclusion

This draft guidance offers clear recommendations to promote ethically responsible and scientifically robust clinical trial designs, highlighting the agency's dedication to advancing research and ensuring trial safety. It prioritizes participant well-being while enabling researchers to derive meaningful insights through the careful and appropriate use of tissue biopsies.

Aureole’s analysis of potential Gaps and Solutions

Risk and Accessibility

• Potential Gap: Current emphasis on minimizing high-risk biopsies could hinder rare disease research where such methods are indispensable.

• Potential Solution: Allow high-risk biopsies under strict safeguards, supported by comprehensive patient education and informed consent.

Integration of Non-Invasive Alternatives

• Potential Gap: Limited focus on emerging non-invasive technologies like liquid biopsies and advanced imaging in the guidance.

• Potential Solution: Mandate feasibility studies to assess the use of non-invasive alternatives, improving safety and trial participation.

Clarity on Optional Biopsies

• Potential Gap: Optional biopsies risk incomplete datasets and unreliable endpoints.

• Potential Solution: Introduce incentives, such as extended follow-ups or additional care, to encourage participation in optional biopsies and enhance dataset robustness.

Diversity and Representation

• Potential Gap: Biopsy requirements may disproportionately affect underserved populations due to logistical and cultural barriers.

• Potential Solution: Design equitable trials with geographically dispersed facilities, cultural competency training, and localized outreach to improve access and participation.

Transforming Clinical Trials

Advancing Precision Medicine

• Potential Gap: Limited integration of genomics and AI for refining biomarkers and trial design.

• Potential Solution: Leverage advanced technologies to develop targeted and patient-friendly trial designs.

Strengthening Patient-Centricity

• Potential Gap: Informed consent does not extend to participatory trial planning.

• Potential Solution: Incorporate patient feedback on biopsy protocols to align with participant expectations and enhance compliance.

Promoting Global Regulatory Alignment

• Potential Gap: Limited focus on harmonizing biopsy requirements with international standards.

• Potential Solution: Align biopsy protocols globally to streamline multicenter trials and reduce redundancies.

Adopting Adaptive Trial Designs

• Potential Gap: Lack of provisions for dynamic biopsy protocols based on interim analyses.

• Potential Solution: Implement adaptive trial designs to optimize biopsy requirements, reducing unnecessary procedures while maintaining data integrity.

Leveraging Real-World Data

• Potential Gap: Limited emphasis on embedding biopsy protocols in real-world studies for longitudinal insights.

• Potential Solution: Integrate biopsy procedures into real-world data studies to bridge gaps between controlled trials and practical applications.

Final Remarks

The draft guidance provides a strong foundation but leaves gaps in critical areas such as risk management, non-invasive alternatives, diversity, and the use of advanced technologies. Addressing these gaps with innovative and patient-centric solutions can enhance clinical trial designs, improve inclusivity, and accelerate medical advancements.

References:

1. U.S. Food and Drug Administration. FDA releases draft guidance on the inclusion of tissue biopsies in clinical trials. Published January 6, 2025. Accessed January 7, 2024. Available at: https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-including-tissue-biopsies-clinical-trials

2. U.S. Food and Drug Administration. Draft guidance for industry, investigators, institutions, and institutional review boards: considerations for including tissue biopsies in clinical trials. Published January 6, 2025. Accessed January 7, 2024. Available at: https://www.fda.gov/media/184884/download